RUA Life Sciences has reported its interim results for the six-months to September 22, detailing progress across each of its four business units. The company has delivered strong revenue growth of 56%, while maintaining tight control on its cost base, such that the end of period cash balance was £2.5m vs £3.0m at March 2022, ahead of an expected R&D Tax Credit. Discussions with the FDA on the vascular graft devices have progressed and RUA sees the requirements of the human clinical study much re ....
